Compassionate Use of Hydroxychloroquine in Clinical Practice for Patients With Mild to Severe COVID-19 in a French University Hospital
Clicks: 70
ID: 273449
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
20.7
/100
70 views
9 readers
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #873 of 1,084 articles by views in clinical infectious diseases
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,084 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
AbstractBackground. Data from nonrandomized studies have suggested that hydroxychloroquine could be an effective therapeutic agent against coronavirus disease 2
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (18 words).
Try re-searching for a better abstract.
| Reference Key |
olivierclinicalcompassionate
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Paccoud, Olivier;Tubach, Florence;Baptiste, Amandine;Bleibtreu, Alexandre;Hajage, David;Monsel, Gentiane;Tebano, Gianpiero;Boutolleau, David;Klement, Elise;Godefroy, Nagisa;Palich, Romain;Itani, Oula;Faiçal, Antoine;Valantin, Marc-Antoine;Tubiana, Roland;Burrel, Sonia;Calvez, Vincent;Caumes, Eric;Marcelin, Anne-Geneviève;Pourcher, Valérie; |
| Journal | clinical infectious diseases |
| Year | Year not found |
| DOI |
DOI not found
|
| URL | |
| Keywords |
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.